PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Articles|May 13, 2020
Mylan to Partner with Gilead for Remdesivir Access Expansion
Author(s)Pharmaceutical Technology Editors
Through the agreement, Mylan will manufacture and distribute remdesivir in 127 low- and middle-income countries, including India.
Advertisement
Mylan announced on May 12, 2020 that it is collaborating with Gilead Sciences to supply investigational antiviral remdesivir for the treatment of COVID-19.
Through the agreement, Mylan will manufacture and distribute remdesivir in 127 low- and middle-income countries, including India, according to a press release. Additionally, Mylan will work to develop a bioequivalent version of remdesivir and its own active pharmaceutical ingredient for sterile powder lyophilized vials for administration of the medicine by intravenous infusion.
"The unprecedented development timeline at Mylan is a direct reflection of the investments we've made to build a first-class, global research and manufacturing platform, including strong technical expertise in injectable dosage forms,” said Rajiv Malik, president, Mylan, in the press release. “Today's announcement is another example of how Mylan's unique global infrastructure and expertise empower other companies to expand their own reach by providing more patients with access to critical medicines worldwide."
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement